AI assistant
Pacira BioSciences, Inc. — Director's Dealing 2011
Feb 2, 2011
32125_dirs_2011-02-02_4e64ac51-561e-42e6-ab8f-eed93e3e2c58.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2011-02-02
Reporting Person: Sanderling Venture Partners VI LP (10% Owner)
Reporting Person: Sanderling Ventures Management VI (10% Owner)
Reporting Person: Sanderling VI Beteiligungs GmbH & Co KG (10% Owner)
Reporting Person: Sanderling VI Limited Partnership (10% Owner)
Reporting Person: Sanderling Venture Partners VI Co Investment Fund LP (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 125800 | Direct |
| Common Stock | 55788 | Direct |
| Common Stock | 1995 | Direct |
| Common Stock | 2377 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | $ | Common Stock (736583) | Direct | ||
| Series A Convertible Preferred Stock | $ | Common Stock (14877) | Direct | ||
| Series A Convertible Preferred Stock | $ | Common Stock (24871) | Direct | ||
| Series A Convertible Preferred Stock | $ | Common Stock (29634) | Direct | ||
| Series A Convertible Preferred Stock | $ | Common Stock (681715) | Direct | ||
| Common Stock Warrant (Right to Buy) | $2.69 | 2014-01-21 | Common Stock (17973) | Direct | |
| Common Stock Warrant (Right to Buy) | $2.69 | 2014-01-21 | Common Stock (629) | Direct | |
| Common Stock Warrant (Right to Buy) | $2.69 | 2014-01-21 | Common Stock (749) | Direct | |
| Common Stock Warrant (Right to Buy) | $2.69 | 2014-01-21 | Common Stock (17839) | Direct | |
| Common Stock Warrant (Right to Buy) | $13.44 | 2017-12-29 | Common Stock (20220) | Direct | |
| Common Stock Warrant (Right to Buy) | $13.44 | 2017-12-29 | Common Stock (708) | Direct | |
| Common Stock Warrant (Right to Buy) | $13.44 | 2017-12-29 | Common Stock (843) | Direct | |
| Common Stock Warrant (Right to Buy) | $13.44 | 2017-12-29 | Common Stock (20069) | Direct | |
| Convertible Promissory Notes | $ | Common Stock (344355) | Direct | ||
| Convertible Promissory Notes | $ | Common Stock (12058) | Direct | ||
| Convertible Promissory Notes | $ | Common Stock (14366) | Direct | ||
| Convertible Promissory Notes | $ | Common Stock (341788) | Direct | ||
| Convertible Promissory Notes | $ | Common Stock (129445) | Direct | ||
| Convertible Promissory Notes | $ | Common Stock (5400) | Direct | ||
| Convertible Promissory Notes | $ | Common Stock (128479) | Direct | ||
| Convertible Promissory Notes | $ | Common Stock (4533) | Direct |
Footnotes
F1: The securities are held by Sanderling Venture Partners VI, L.P.
F2: The securities are held by Sanderling Ventures Management VI.
F3: The securities are held by Sanderling VI Beteiligungs GmbH & Co. KG.
F4: The securities are held by Sanderling VI Limited Partnership.
F5: The Series A Convertible Preferred Stock has no expiration date and each share of Series A Convertible Preferred Stock will automatically convert into one share of Common Stock upon the consummation of the Issuer's initial public offering.
F6: The securities are held by Sanderling Venture Partners VI Co-Investment Fund.
F7: All principal and accrued interest on the Convertible Promissory Notes will automatically convert into shares of Common Stock upon the consummation of the Issuer's initial public offering.
F8: All principal on the Convertible Promissory Notes will automatically convert into shares of Common Stock upon the consummation of the Issuer's initial public offering at a conversion price equal to the per share price of the Common Stock sold in the Issuer's initial public offering.